Alzheimer's-associated Aβ oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal

Toxicology and Applied Pharmacology

Volumn 240, Issue 2, 2009, Pages 189-197

  Pitt, Jason ^a   Roth, William ^a   Lacor, Pascale ^a   Smith III, Amos B ^b,c   Blankenship, Matthew ^d   Velasco, Pauline ^a   De Felice, Fernanda ^e   Breslin, Paul ^b,f   Klein, William L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MONELL CHEMICAL SENSES CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d WESTERN ILLINOIS UNIVERSITY   (United States)

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^f RUTGERS UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Oligomer; Olive oil; Synapse

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; DREBRIN; OLEOCANTHAL; PHENOL DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DENDRITIC SPINE; HIPPOCAMPUS; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; NEUROPROTECTION; OLIGOMERIZATION; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; SYNAPSE;

ALDEHYDES; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; ANTIGEN-ANTIBODY REACTIONS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLUORESCENT ANTIBODY TECHNIQUE; HIPPOCAMPUS; HUMANS; IMMUNOBLOTTING; MICROSCOPY, CONFOCAL; MOLECULAR WEIGHT; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PHENOLS; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; SYNAPSES;

EID: 70349241517     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.07.018     Document Type: Article

References (52)

1. Abdul H.M., Sultana R., St Clair D.K., Markesbery W.R., and Butterfield D.A. Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. Free Radic. Biol. Med. 45 10 (2008 Nov. 15) 1420-1425
2. Anker J.N., Hall W.P., Lambert M.P., Velasco P.T., Mrksich M., Klein W.L., and Van Duyne R.P. Detection and identification of bioanalytes with high resolution LSPR spectroscopy and MALDI mass spectrometry. J. Phys. Chem. 113 15 (2009) 5891-5894
3. Aoki C., Sekino Y., Hanamura K., Fujisawa S., Mahadomrongkul V., Ren Y., and Shirao T. Drebrin A is a postsynaptic protein that localizes in vivo to the submembranous surface of dendritic sites forming excitatory synapses. J. Comp. Neurol. 483 4 (2005) 383-402
4. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., and Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6 8 (2000) 916-919
5. Bazoti F.N., Bergquist J., Markides K.E., and Tsarbopoulos A. Noncovalent interaction between amyloid-beta-peptide (1-40) and oleuropein studied by electrospray ionization mass spectrometry. J. Am. Soc. Mass Spectrom. 17 4 (2006 Apr) 568-575
6. Bazoti F.N., Bergquist J., Markides K., and Tsarbopoulos A. Localization of the noncovalent binding site between amyloid-beta-peptide and oleuropein using electrospray ionization FT-ICR mass spectrometry. J. Am. Soc. Mass Spectrom. 19 8 (2008) 1078-1085
7. Beauchamp G.K., Keast R.S.J., Morel D., Lin J., Pika J., Han Q., Lee C., Smith A.B., and Breslin P.A.S. Phytochemistry: ibuprofen-like activity in extra-virgin olive oil. Nature 437 7055 (2005 Sep. 1) 45-46
8. Blasko I., Apochal A., Boeck G., Hartmann T., Grubeck-Loebenstein B., and Ransmayr G. Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells. Neurobiol. Dis. 8 6 (2001) 1094-1101
9. Bolte S., and Cordelieres F.P. A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 224 Pt. 3 (2006) 213-232
10. Cerf E., Sarroukh R., Tamamizu-Kato S., Breydo L., Derclaye S., Dufrene Y., Narayanaswami V., Goormaghtigh E., Ruysschaert J., and Raussens V. Anti-parallel beta-sheet - a signature structure of the oligomeric amyloid-beta peptide. Biochem. J. 421 3 (2009) 415-423
11. De Felice F.G., Vieira M.N.N., Saraiva L.M., Figueroa-Villar J.D., Garcia-Abreu J., Liu R., Chang L., Klein W.L., and Ferreira S.T. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. FASEB J. 18 12 (2004) 1366-1372
12. De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T., and Klein W.L. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 282 15 (2007 Apr. 13) 11590-11601
13. De Felice F.G., Wu D., Lambert M.P., Fernandez S.J., Velasco P.T., Lacor P.N., Bigio E.H., Jerecic J., Acton P.J., Shughrue P.J., Chen-Dodson E., Kinney G.G., and Klein W.L. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol. Aging 29 9 (2008 Sep) 1334-1347
14. De Felice F.G., Vieira M.N.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., Viola K.L., Zhao W., Ferreira S.T., and Klein W.L. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. U. S. A. 106 6 (2009) 1971-1976
15. Deshpande A., Mina E., Glabe C., and Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 26 22 (2006) 6011-6018
16. Durairajan S.S.K., Yuan Q., Xie L., Chan W., Kum W., Koo I., Liu C., Song Y., Huang J., Klein W.L., and Li M. Salvianolic acid B inhibits Abeta fibril formation and disaggregates preformed fibrils and protects against Abeta-induced cytotoxicty. Neurochem. Int. 52 4-5 (2008 Mar.-Apr) 741-750
17. Engelhart M.J., Geerlings M.I., Ruitenberg A., van Swieten J.C., Hofman A., Witteman J.C.M., and Breteler M.M.B. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287 24 (2002 Jun. 26) 3223-3229
18. Georganopoulou D.G., Chang L., Nam J., Thaxton C.S., Mufson E.J., Klein W.L., and Mirkin C.A. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 102 7 (2005) 2273-2276
19. Grundman M., and Black R. O3-04-05: clinical trials of bapineuzumab, a beta-amyloid-targeted immunotherapy in patients with mild to moderate Alzheimer's disease. Alzheimer's Dementia 4 4, Supplement 1 (2008) T166
20. Hardy J.A., and Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256 5054 (1992 Apr. 10) 184-185
21. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 5580 (2002) 353-356
22. Ho L., Chen L.H., Wang J., Zhao W., Talcott S.T., Ono K., Teplow D., Humala N., Cheng A., Percival S.S., Ferruzzi M., Janle E., Dickstein D.L., and Pasinetti G.M. Heterogeneity in Red Wine Polyphenolic Contents Differentially Influences Alzheimer's Disease-type Neuropathology and Cognitive Deterioration. J. Alzheimers. Dis. 16 1 (2009) 59-72
23. Hock C., Maddalena A., Raschig A., Muller-Spahn F., Eschweiler G., Hager K., Heuser I., Hampel H., Muller-Thomsen T., Oertel W., Wienrich M., Signorell A., Gonzalez-Agosti C., and Nitsch R.M. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 10 1 (2003) 1-6
24. Ivanov A., Esclapez M., Pellegrino C., Shirao T., and Ferhat L. Drebrin A regulates dendritic spine plasticity and synaptic function in mature cultured hippocampal neurons. J. Cell. Sci. 122 Pt 4 (2009) 524-534
25. Jacobsen J.S., Wu C., Redwine J.M., Comery T.A., Arias R., Bowlby M., Martone R., Morrison J.H., Pangalos M.N., Reinhart P.H., and Bloom F.E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 103 13 (2006) 5161-5166
26. Jicha G.A. Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?. Expert Opin. Biol. Ther. 9 4 (2009) 481-491
27. Knobloch M., Farinelli M., Konietzko U., Nitsch R.M., and Mansuy I.M. Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J. Neurosci. 27 29 (2007) 7648-7653
28. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., Lambert M.P., Velasco P.T., Bigio E.H., Finch C.E., Krafft G.A., and Klein W.L. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 24 45 (2004) 10191-10200
29. Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., Viola K.L., and Klein W.L. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27 4 (2007 Jan. 24) 796-807
30. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95 11 (1998 May 26) 6448-6453
31. Lambert M.P., Viola K.L., Chromy B.A., Chang L., Morgan T.E., Yu J., Venton D.L., Krafft G.A., Finch C.E., and Klein W.L. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79 3 (2001) 595-605
32. Lambert M.P., Velasco P.T., Chang L., Viola K.L., Fernandez S., Lacor P.N., Khuon D., Gong Y., Bigio E.H., Shaw P., De Felice F.G., Krafft G.A., and Klein W.L. Monoclonal antibodies that target pathological assemblies of Abeta. J. Neurochem. 100 1 (2007 Jan) 23-35
33. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., and Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 7082 (2006) 352-357
34. McKee A.C., Carreras I., Hossain L., Ryu H., Klein W.L., Oddo S., LaFerla F.M., Jenkins B.G., Kowall N.W., and Dedeoglu A. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 1207 (2008 May 1) 225-236
35. Nicoll J.A.R., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9 4 (2003) 448-452
36. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., and LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39 3 (2003) 409-421
37. Orgogozo J., Gilman S., Dartigues J., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., and Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 1 (2003) 46-54
38. Ono K., Condron M.M., Ho L., Wang J., Zhao W., Pasinetti G.M., and Teplow D.B. Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cytotoxicity. J. Biol. Chem. 283 47 (2008 Nov 21) 32176-32187
39. Small D.H. The Sixth International Conference on Alzheimer's disease, Amsterdam, The Netherlands, July 1998. The amyloid cascade hypothesis debate: emerging consensus on the role of A beta and amyloid in Alzheimer's disease. Amyloid 5 4 (1998 Dec) 301-304
40. Smith A.B., Han Q., Breslin P.A.S., and Beauchamp G.K. Synthesis and assignment of absolute configuration of (-)-oleocanthal: a potent, naturally occurring non-steroidal anti-inflammatory and anti-oxidant agent derived from extra virgin olive oils. Org. Lett. 7 22 (2005 Oct 27) 5075-5078
41. Solfrizzi V., Colacicco A.M., D'Introno A., Capurso C., Torres F., Rizzo C., Capurso A., and Panza F. Dietary intake of unsaturated fatty acids and age-related cognitive decline: a 8.5-year follow-up of the Italian Longitudinal Study on Aging. Neurobiol. Aging 27 11 (2006 Nov) 1694-1704
42. Takahashi H., Sekino Y., Tanaka S., Mizui T., Kishi S., and Shirao T. Drebrin-dependent actin clustering in dendritic filopodia governs synaptic targeting of postsynaptic density-95 and dendritic spine morphogenesis. J. Neurosci. 23 16 (2003) 6586-6595
43. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., and Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30 4 (1991 Oct) 572-580
44. Viola K.L., Velasco P.T., and Klein W.L. Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). J. Nutr. Health Aging 12 1 (2008) 51S-57S
45. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 6880 (2002) 535-539
46. Wang H., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., Viola K.L., Klein W.L., Stine W.B., Krafft G.A., and Trommer B.L. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924 2 (2002 Jan. 11) 133-140
47. Wang Z., Chang L., Klein W.L., Thatcher G.R.J., and Venton D.L. Per-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers. J. Med. Chem. 47 13 (2004 Jun. 17) 3329-3333
48. Wang J., Ho L., Zhao W., Ono K., Rosensweig C., Chen L., Humala N., Teplow D.B., and Pasinetti G.M. Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J. Neurosci. 28 25 (2008 Jun. 18) 6388-6392
49. Wu Y., Wu Z., Butko P., Christen Y., Lambert M.P., Klein W.L., Link C.D., and Luo Y. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J. Neurosci. 26 50 (2006) 13102-13113
50. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., and Cole G.M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280 7 (2005) 5892-5901
51. Yu J., Bakhos L., Chang L., Holterman M.J., Klein W.L., and Venton D.L. Per-6-substituted beta-cyclodextrin libraries inhibit formation of beta-amyloid-peptide (A beta)-derived, soluble oligomers. J. Mol. Neurosci. 19 1-2 (2002 Aug.-Oct) 51-55
52. Yu L., Edalji R., Harlan J.E., Holzman T.F., Lopez A.P., Labkovsky B., Hillen H., Barghorn S., Ebert U., Richardson P.L., Miesbauer L., Solomon L., Bartley D., Walter K., Johnson R.W., Hajduk P.J., and Olejniczak E.T. Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry 48 9 (2009) 1870-1877